| Literature DB >> 26563102 |
Chantal den Daas1, Maaike Goenee2, Bouko H W Bakker3, Hanneke de Graaf4, Eline L M Op de Coul5.
Abstract
BACKGROUND: Early detection and treatment of STI/HIV are public health priorities. Our objective was to compare characteristics of men who have sex with men (MSM) in Dutch data available in 2010 from EMIS, an international internet survey, Schorer Monitor, a Dutch internet survey, and data from STI- clinic visits, since these might be subject to different and unknown biases.Entities:
Mesh:
Year: 2015 PMID: 26563102 PMCID: PMC4643504 DOI: 10.1186/s12889-015-2445-3
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Questions
| Variable | EMIS | SMON (translation) | SOAP (translation) |
|---|---|---|---|
| Age | How old are you? | What is your age? | Year of birth |
| Residence | What are the first two digits of your home post-code? | What are the first three digits of your home post-code? | Post-code (4 digits) |
| Ethnicity | Which country were you born in? | Which cultural background did you grow-up with? | Ethnic group |
| Number of partners | How many different non-steady male partners have you had sex with in the last 12 months? | How many different non-steady male partners have you had sex with in the last 6 months? | How many persons have you had sexual contact with in the last 6 months? |
| Condom use last partner | Did he [the non-steady sex partner you most recently had sex with] use a condom during AI? | Did he [the non-steady sex partner you most recently had sex with] use a condom during AI? | Did you use condom(s) during the last sexual contact? |
| Drug use | When was the last time you consumed X? (recode: yes/no w/i 6 mo) | X – How often did you use in the last 6 months? | Intravenous drug use |
| STI | When were you last diagnosed with X? | In the last 12 months, did you receive a positive STI diagnosis? (X yes/no) | Laboratory diagnosis |
| HIV | Have you ever received an HIV test result? (status in answer options) | Have you ever been tested for HIV? + What was the result? | Diagnosis/Earlier HIV-test |
AI anal intercourse, STI sexually transmitted infection, HIV human immunodeficiency virus
Baseline characteristics of the study population, N (%) unless indicated otherwise, stratified by database
| EMIS | SMON | SOAP | ||
|---|---|---|---|---|
| Age | Range | 14–87 | 14–86 | 16–76 |
| Mean (SD) | 39.81 (12.34) | 38.36 (13.51) | 37.99 (11.66) | |
| Median | 40 | 39 | 38 | |
| Residence | Amsterdam | 1019 (26.9) | 706 (19.6) | 1433 (37.7) |
| Rotterdam | 185 (4.9) | 175 (4.9) | 215 (5.7) | |
| The Hague | 167 (4.4) | 138 (3.8) | 170 (4.5) | |
| Utrecht | 122 (3.2) | 144 (4.0) | 93 (2.4) | |
| Other areas | 1881 (49.7) | 2280 (63.3) | 1785 (47.0) | |
| Missing | 413 (10.9) | 159 (4.4) | 104 (2.7) | |
| Ethnicity | Dutch | 2833 (74.8) | 3131 (86.9) | 3114 (81.9) |
| Not Dutch | 849 (22.4) | 458 (12.7) | 679 (17.9) | |
| Missing | 105 (2.8) | 13 (0.4) | 7 (0.2) | |
| Not Dutch | Turkey, North Africa | 17 (2.0) | 23 (5.0) | 47 (6.9) |
| Specified | Surinam, Netherlands Antilles | 32 (3.8) | 68 (14.9) | 95 (14.0) |
| Eastern Europe | 103 (12.1) | 21 (4.6) | 73 (10.8) | |
| Sub-Sahara Africa | 26 (3.1) | 11 (2.4) | 15 (2.2) | |
| Central and South America | 86 (10.1) | 22 (4.8) | 85 (12.5) | |
| Rest of Europe | 418 (49.2) | 211 (46.1) | 64 (9.4) | |
| Asia | 83 (9.8) | 74 (16.2) | 69 (10.2) | |
| N. America, Canada, Oceania | 84 (9.9) | 28 (6.1) | 231 (34.0) | |
| Number | 1–2 | 527 (13.9) | 585 (16.2) | 940 (24.7) |
| of | 3–5 | 674 (17.8) | 796 (22.1) | 1107 (29.1) |
| Partners | 6–10 | 570 (15.1) | 512 (14.2) | 740 (19.5) |
| 11–20 | 504 (13.3) | 392 (10.9) | 388 (10.2) | |
| 21–50 | 437 (11.5) | 236 (6.6) | 250 (6.6) | |
| >50 | 250 (6.6) | 49 (1.4) | 338 (8.9) | |
| Missing | 825 (21.8) | 1032 (28.7) | 37 (1.0) | |
| CLP | Yes | 1485 (39.2) | 753 (20.9) | 872 (22.9) |
| Missing | 851 (22.5) | 2363 (65.6) | 2321 (61.1) | |
| Substances | Alcohol | 3469 (91.6) | 2521 (72.1) | – |
| w/i 6 mo. | Poppers | 1640 (43.3) | 1348 (38.6) | – |
| Viagra | 1081 (28.5) | 932 (26.7) | – | |
| Cannabis | 905 (23.9) | 634 (18.1) | – | |
| Ecstasy | 708 (18.7) | 502 (14.4) | – | |
| Speed | 249 (6.6) | 157 (4.5) | – | |
| Methamphetamine | 81 (2.1) | 57 (1.6) | – | |
| GHB | 493 (13.0) | 408 (11.7) | – | |
| Cocaine | 375 (9.9) | 257 (7.4) | – | |
| Missing | 0 (0.0) | 107 (3.0) | – | |
| STI | Gonorrhoea | 194 (5.2) | 174 (5.0) | 322 (8.5) |
| Chlamydia | 260 (7.0) | 235 (6.7) | 362 (9.5) | |
| Syphilis | 122 (3.3) | 136 (3.9) | 120 (3.2) | |
| Hepatitis B | 435 (11.5) | 383 (11.0) | 144 (3.8) | |
| Hepatitis C | 136 (3.6) | 56 (1.6) | 0 (0.0) | |
| Herpes | 28 (0.7) | 34 (1.0) | 22 (0.6) | |
| Warts | 102 (2.7) | 81 (2.3) | 90 (2.4) | |
| Other STI | – | 25 (0.7) | 20 (0.5) | |
| (Skin) diseases | – | 2 (0.1) | 108 (2.8) | |
| Missing Mean | 32 (0.8) | 107 (3.0) | 2 (0.1) | |
| HIV status | HIV+ | 589 (15.6) | 414 (11.5) | 679 (17.9) |
| HIV– | 2408 (63.6) | 2164 (60.1) | 2512 (66.1) | |
| Never tested | 774 (20.4) | 864 (24.0) | 490 (12.9) | |
| Missing | 16 (0.4) | 160 (4.4) | 119 (3.1) |
CLP Condom use with last sexual partner, GHB gamma-hydroxybutyraat, mo. months, STI sexually transmitted diseases, HIV human immunodeficiency virus
Logistic regression analyses of characteristics of participants with STI in EMIS, SMON, and SOAPa
| EMIS | SMON | SOAP | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STI+ | Univariable | Multivariable | STI+ | Univariable | Multivariable | STI+ | Univariable | Multivariable | ||||
| No. | % | OR (95 % CI) | aOR (95 % CI) | No. | % | OR (95 % CI) | aOR (95 % CI) | No. | % | OR (95 % CI) | aOR (95 % CI) | |
| Age group (years)b | ||||||||||||
| < 35 | 242 | 17.9 | 1.0 | 1.0 | 227 | 15.1 | 1.0 | 1.0 | 409 | 26.2 | 1.0 | 1.0 |
| 35°F49 | 439 | 26.9 |
| 1.1 (0.8–1.4) | 338 | 25.5 |
| 0.9 (0.6–1.2) | 401 | 25.0 | 0.9 (0.8–1.1) | 1.0 (0.7–1.3) |
| > 49 | 250 | 31.1 |
| 1.2 (0.9–1.7) | 223 | 28.9 |
| 1.2 (0.8–1.8) | 172 | 27.1 | 1.0 (0.9–1.3) | 0.8 (0.6–1.2) |
| Residenceb | ||||||||||||
| Outside Amsterdam | 514 | 21.8 | 1.0 | 1.0 | 510 | 18.6 | 1.0 | 1.0 | 586 | 25.9 | 1.0 | 1.0 |
| Amsterdam | 318 | 31.2 |
| 1.0 (0.8–1.3) | 255 | 36.1 |
|
| 366 | 25.5 | 1.0 (0.8–1.1) | 0.9 (0.7–1.2) |
| Ethnicity | ||||||||||||
| Dutch | 685 | 24.2 | 1.0 | 1.0 | 671 | 21.4 | 1.0 | 1.0 | 776 | 24.9 | 1.0 | 1.0 |
| Other | 246 | 25.8 | 1.0 (0.9–1.3) | 1.1 (0.8–1.4) | 117 | 24.8 | 1.2 (1.0–1.5) | 1.0 (0.6–1.5) | 206 | 30.0 |
|
|
| Number of partnersb | ||||||||||||
| 1–2 | 80 | 15.2 | 1.0 | 1.0 | 83 | 14.2 | 1.0 | 1.0 | 250 | 26.6 | 1.0 | 1.0 |
| 3–5 | 130 | 19.3 | 1.3 (1.0–1.8) | 1.1 (0.7–1.6) | 151 | 19.0 |
| 0.8 (0.5–1.4) | 261 | 23.6 | 0.9 (0.7–1.0) | 0.7 (0.5–1.0) |
| 6–10 | 152 | 26.7 |
| 1.5 (1.0–2.3) | 172 | 33.6 |
| 1.4 (0.8–2.3) | 216 | 29.2 | 1.1 (0.9–1.4) | 0.9 (0.6–1.3) |
| 11–20 | 154 | 30.6 |
|
| 141 | 36.0 |
| 1.6 (0.9–2.7) | 88 | 22.7 | 0.8 (0.6–1.1) | 0.8 (0.5–1.2) |
| 21–50 | 169 | 38.7 |
|
| 113 | 47.9 |
|
| 58 | 23.2 | 0.8 (0.6–1.2) | 0.6 (0.3–1.1) |
| > 50 | 137 | 54.8 |
|
| 27 | 55.1 |
|
| 103 | 30.5 | 1.2 (0.9–1.6) | 1.0 (0.6–1.8) |
| Condom use last partnerb | ||||||||||||
| Yes | 358 | 24.1 | 1.0 | 1.0 | 200 | 26.6 | 1.0 | 1.0 | 235 | 26.9 | 1.0 | 1.0 |
| No | 455 | 31.4 |
|
| 167 | 34.4 |
| 1.1 (0.8–1.5) | 126 | 20.8 |
|
|
| Drugs | ||||||||||||
| No | 207 | 12.9 | 1.0 | 1.0 | 196 | 11.0 | 1.0 | 1.0 | ||||
| Yes 1 | 218 | 23.3 |
|
| 193 | 23.3 |
| 1.2 (0.8–1.8) | ||||
| Yes > 1 | 506 | 40.7 |
|
| 399 | 40.5 |
|
| ||||
| HIVb | ||||||||||||
| Never test | 55 | 7.1 | 1.0 | 1.0 | 37 | 4.3 | 1.0 | 1.0 | 123 | 25.1 | 1.0 | 1.0 |
| HIV+ | 343 | 58.2 |
|
| 255 | 61.6 |
|
| 161 | 23.7 | 0.9 (0.7–1.2) | 0.8 (0.5–1.3) |
| HIV− | 531 | 22.1 |
|
| 488 | 22.6 |
|
| 663 | 26.4 | 1.1 (0.9–1.3) | 1.1 (0.7–1.6) |
95 % CI 95 % confidence interval, OR odds ratio aOR adjusted odds ratio, No. number, STI+ diagnosed or self-reported one or more sexually transmitted diseases in the last 12 months
Bold printed statistics differ, p-values < .05 are considered significant
aVariables are a priori included in multivariable analyses
bFactors differ significantly between databases, p-values < .05 are considered significant
Logistic regression analyses of characteristics of participants with HIV in EMIS, SMON, and SOAPa
| EMIS | SMON | SOAP | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV+ | Univariable | Multivariable | HIV+ | Univariable | Multivariable | HIV+ | Univariable | Multivariable | ||||
| No. | % | OR (95 % CI) | aOR (95 % CI) | No. | % | OR (95 % CI) | aOR (95 % CI) | No. | % | OR (95 % CI) | aOR (95 % CI) | |
| Age group (years) | ||||||||||||
| < 35 | 100 | 7.4 | 1.0 | 1.0 | 81 | 5.7 | 1.0 | 1.0 | 147 | 9.4 | 1.0 | 1.0 |
| 35–49 | 323 | 19.9 |
|
| 216 | 16.4 |
|
| 376 | 23.5 |
|
|
| > 49 | 166 | 20.7 |
|
| 117 | 15.3 |
| 1.4 (0.8–2.5) | 156 | 24.6 |
|
|
| Residence | ||||||||||||
| Outside Amsterdam | 275 | 11.0 | 1.0 | 1.0 | 262 | 9.8 | 1.0 | 1.0 | 273 | 12.1 | 1.0 | 1.0 |
| Amsterdam | 243 | 23.9 |
|
| 147 | 20.9 |
| 1.2 (0.8–1.8) | 396 | 27.6 |
|
|
| Ethnicity | ||||||||||||
| Dutch | 437 | 15.5 | 1.0 | 1.0 | 351 | 11.6 | 1.0 | 1.0 | 565 | 18.1 | 1.0 | 1.0 |
| Other | 152 | 16.0 | 1.0 (0.9–1.3) | 0.8 (0.6–1.1) | 63 | 13.6 | 1.2 (0.9–1.6) | 1.2 (0.7–2.0) | 114 | 16.6 | 0.9 (0.7–1.1) | 1.1 (0.7–1.8) |
| Number of partnersb | ||||||||||||
| 1–2 | 44 | 8.4 | 1.0 | 1.0 | 33 | 5.6 | 1.0 | 1.0 | 122 | 13.0 | 1.0 | 1.0 |
| 3–5 | 90 | 13.4 |
| 1.7 (1.0–2.8) | 81 | 10.2 |
| 1.8 (0.8–3.8) | 154 | 13.9 | 1.0 (0.8–1.4) | 1.1 (0.7–1.7) |
| 6–10 | 88 | 15.5 |
| 1.4 (0.8–2.4) | 75 | 14.6 |
| 1.4 (0.7–3.0) | 149 | 20.1 |
|
|
| 11–20 | 93 | 18.5 |
| 1.7 (1.0–2.8) | 74 | 18.9 |
| 1.3 (0.6–2.9) | 104 | 26.8 |
|
|
| 21–50 | 98 | 22.5 |
| 1.4 (0.9–2.4) | 66 | 28.0 |
| 1.8 (0.8–4.0) | 81 | 32.4 |
|
|
| > 50 | 102 | 41.0 |
|
| 19 | 38.8 |
| 1.9 (0.6–5.7) | 57 | 16.9 | 1.4 (1.0–1.9) |
|
| Condom use last partnerb | ||||||||||||
| Yes | 177 | 12.0 | 1.0 | 1.0 | 87 | 11.6 | 1.0 | 1.0 | 146 | 16.7 | 1.0 | 1.0 |
| No | 346 | 23.9 |
|
| 145 | 30.1 |
|
| 102 | 16.8 | 1.0 (0.8–1.3) | 1.0 (0.7–1.4) |
| Drugs | ||||||||||||
| No | 89 | 5.6 | 1.0 | 1.0 | 58 | 3.5 | 1.0 | 1.0 | ||||
| Yes 1 | 106 | 11.4 |
|
| 74 | 8.9 |
|
| ||||
| Yes > 1 | 394 | 31.8 |
|
| 282 | 28.6 |
|
| ||||
| STIb | ||||||||||||
| No | 246 | 8.7 | 1.0 | 1.0 | 159 | 5.9 | 1.0 | 1.0 | 518 | 18.4 | 1.0 | 1.0 |
| Yes 1 | 198 | 28.9 |
|
| 136 | 24.3 |
|
| 141 | 17.5 | 0.9 (0.8–1.2) | 0.8 (0.5–1.2) |
| Yes > 1 | 145 | 59.2 |
|
| 119 | 52.2 |
|
| 20 | 11.2 |
| 0.6 (0.3–1.3) |
95 % CI 95 % confidence interval, OR odds ratio, aOR adjusted odds ratio, No. number, HIV+ diagnosed or self–reported HIV–positive status
Bold printed statistics differ, p–values < .05 are considered significant
aVariables are a priori included in multivariable analyses
bFactors differ significantly between databases, p–values < .05 are considered significant
Logistic regression analyses of determinants for ‘never tested for HIV’ in EMIS, SMON, and SOAPa
| EMIS | SMON | SOAP | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NT | Univariable | Multivariable | NT | Univariable | Multivariable | NT | Univariable | Multivariable | ||||
| No. | % | OR (95 % CI) | aOR (95 % CI) | No. | % | OR (95 % CI) | aOR (95 % CI) | No. | % | OR (95 % CI) | aOR (95 % CI) | |
| Age group (years) | ||||||||||||
| < 35 | 381 | 28.4 | 1.0 | 1.0 | 476 | 33.7 | 1.0 | 1.0 | 299 | 19.1 | 1.0 | 1.0 |
| 35–49 | 241 | 14.8 |
| 0.6 (0.5–0.9) | 230 | 17.5 |
| 0.7 (0.5–1.1) | 129 | 8.1 |
|
|
| > 49 | 152 | 19.0 |
| 0.8 (0.6–1.2) | 158 | 20.6 |
| 0.8 (0.5–1.4) | 62 | 9.8 |
|
|
| Residence | ||||||||||||
| Outside Amsterdam | 586 | 25.0 | 1.0 | 1.0 | 738 | 27.9 | 1.0 | 1.0 | 376 | 16.6 | 1.0 | 1.0 |
| Amsterdam | 106 | 10.4 |
|
| 76 | 10.8 |
|
| 88 | 6.1 |
|
|
| Ethnicity | ||||||||||||
| Dutch | 623 | 22.1 | 1.0 | 1.0 | 771 | 25.4 | 1.0 | 1.0 | 407 | 13.1 | 1.0 | 1.0 |
| Other | 151 | 15.9 |
| 1.2 (0.9–1.6) | 93 | 20.0 |
| 0.9 (0.5–1.6) | 83 | 12.1 | 0.9 (0.7–1.2) | 1.0 (0.6–1.6) |
| Number of partnersb | ||||||||||||
| 1–2 | 151 | 28.7 | 1.0 | 1.0 | 208 | 35.6 | 1.0 | 1.0 | 188 | 20.0 | 1.0 | 1.0 |
| 3–5 | 135 | 20.1 |
|
| 194 | 24.4 |
| 0.7 (0.4–1.1) | 180 | 16.3 | 0.8 (0.6–1.0) |
|
| 6–10 | 84 | 14.8 |
|
| 67 | 13.1 |
|
| 68 | 9.2 |
|
|
| 11–20 | 65 | 12.9 |
|
| 48 | 12.2 |
|
| 17 | 4.4 |
|
|
| 21–50 | 43 | 9.9 |
|
| 16 | 6.8 |
|
| 10 | 4.0 |
|
|
| > 50 | 18 | 7.2 |
|
| 3 | 6.1 |
|
| 21 | 6.2 |
|
|
| Condom use last partner | ||||||||||||
| Yes | 235 | 15.9 | 1.0 | 1.0 | 128 | 17.1 | 1.0 | 1.0 | 133 | 15.3 | 1.0 | 1.0 |
| No | 218 | 15.0 | 0.9 (0.8–1.1) | 1.1 (0.8–1.4) | 84 | 17.5 | 1.0 (0.8–1.4) | 1.4 (0.9–2.0) | 77 | 12.7 | 0.8 (0.6–1.1) | 0.7 (0.5–1.0) |
| Drugs | ||||||||||||
| No | 485 | 30.3 | 1.0 | 1.0 | 579 | 34.4 | 1.0 | 1.0 | ||||
| Yes 1 | 177 | 19.1 |
| 0.8 (0.6–1.1) | 181 | 21.8 |
|
| ||||
| Yes > 1 | 112 | 9.0 |
|
| 104 | 10.5 |
|
| ||||
| STIb | ||||||||||||
| No | 719 | 25.3 | 1.0 | 1.0 | 827 | 30.5 | 1.0 | 1.0 | 367 | 13.0 | 1.0 | 1.0 |
| Yes 1 | 49 | 7.2 |
|
| 36 | 6.4 |
|
| 98 | 12.2 | 0.9 (0.7–1.2) | 1.0 (0.6–1.4) |
| Yes > 1 | 6 | 2.4 |
|
| 1 | 0.4 |
| 0.0 (0.0–xx) | 25 | 14.0 | 1.1 (0.7–1.7) | 0.9 (0.4–2.1) |
95 % CI 95 % confidence interval, OR odds ratio, aOR adjusted odds ratio, No. number, NT never having tested for HIV
Bold printed statistics differ, p–values < .05 are considered significant
aVariables are a priori included in multivariable analyses
bFactors differ significantly between databases, p-values < .05 are considered significant